Literature DB >> 23219374

Obesity and prostate cancer: weighing the evidence.

Emma H Allott1, Elizabeth M Masko, Stephen J Freedland.   

Abstract

CONTEXT: Obesity and prostate cancer (PCa) affect substantial proportions of Western society. Mounting evidence, both epidemiologic and mechanistic, for an association between the two is of public health interest. An improved understanding of the role of this modifiable risk factor in PCa etiology is imperative to optimize screening, treatment, and prevention.
OBJECTIVE: To consolidate and evaluate the evidence for an epidemiologic link between obesity and PCa, in addition to examining the proposed underlying molecular mechanisms. EVIDENCE ACQUISITION: A PubMed search for relevant articles published between 1991 and July 2012 was performed by combining the following terms: obesity, BMI, body mass index and prostate cancer risk, prostate cancer incidence, prostate cancer mortality, radical prostatectomy, androgen-deprivation therapy, external-beam radiation, brachytherapy, prostate cancer and quality of life, prostate cancer and active surveillance, in addition to obesity, BMI, body mass index and prostate cancer and insulin, insulin-like growth factor, androgen, estradiol, leptin, adiponectin, and IL-6. Articles were selected based on content, date of publication, and relevancy, and their references were also searched for relevant articles. EVIDENCE SYNTHESIS: Increasing evidence suggests obesity is associated with elevated incidence of aggressive PCa, increased risk of biochemical failure following radical prostatectomy and external-beam radiotherapy, higher frequency of complications following androgen-deprivation therapy, and increased PCa-specific mortality, although perhaps a lower overall PCa incidence. These results may in part relate to difficulties in detecting and treating obese men. However, multiple molecular mechanisms could explain these associations as well. Weight loss slows PCa in animal models but has yet to be fully tested in human trials.
CONCLUSIONS: Obesity appears to be linked with aggressive PCa. We suggest clinical tips to better diagnose and treat obese men with PCa. Whether reversing obesity slows PCa growth is currently unknown, although it is an active area of research.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219374      PMCID: PMC3597763          DOI: 10.1016/j.eururo.2012.11.013

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  97 in total

1.  Weight change and prostate cancer incidence and mortality.

Authors:  Julie K Bassett; Gianluca Severi; Laura Baglietto; Robert J MacInnis; Hoa N Hoang; John L Hopper; Dallas R English; Graham G Giles
Journal:  Int J Cancer       Date:  2012-02-28       Impact factor: 7.396

2.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis.

Authors:  S F Shariat; B Andrews; M W Kattan; J Kim; T M Wheeler; K M Slawin
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

3.  Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile.

Authors:  Ricardo J T Ribeiro; Cátia P D Monteiro; Virginia F P M Cunha; Andreia S M Azevedo; Maria J Oliveira; Rosário Monteiro; Avelino M Fraga; Paulo Príncipe; Carlos Lobato; Francisco Lobo; António Morais; Vitor Silva; José Sanches-Magalhães; Jorge Oliveira; João T Guimarães; Carlos M S Lopes; Rui M Medeiros
Journal:  Cell Physiol Biochem       Date:  2012-03-01

4.  Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.

Authors:  Stephen J Freedland; Elizabeth A Platz; Joseph C Presti; William J Aronson; Christopher L Amling; Christopher J Kane; Martha K Terris
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

5.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 6.  Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis.

Authors:  Mari-Anne Rowlands; David Gunnell; Ross Harris; Lars J Vatten; Jeff M P Holly; Richard M Martin
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

7.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.

Authors:  A Hobisch; I E Eder; T Putz; W Horninger; G Bartsch; H Klocker; Z Culig
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

Review 8.  The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.

Authors:  Helmut Bonkhoff; Richard Berges
Journal:  Eur Urol       Date:  2008-11-06       Impact factor: 20.096

Review 9.  Obesity and prostate cancer: epidemiology and clinical implications.

Authors:  W Cooper Buschemeyer; Stephen J Freedland
Journal:  Eur Urol       Date:  2007-05-02       Impact factor: 20.096

10.  Prostate cancer cell proliferation is influenced by leptin.

Authors:  Ponnandai Somasundar; Krista A Frankenberry; Heath Skinner; Giridhar Vedula; David W McFadden; Dale Riggs; Barbara Jackson; Reyna Vangilder; Stanley M Hileman; Linda C Vona-Davis
Journal:  J Surg Res       Date:  2004-05-01       Impact factor: 2.192

View more
  192 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment.

Authors:  M A Liss; J M Schenk; A V Faino; L F Newcomb; H Boyer; J D Brooks; P R Carroll; A Dash; M D Fabrizio; M E Gleave; P S Nelson; M L Neuhouser; J T Wei; Y Zheng; J L Wright; D W Lin; I M Thompson
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-07-19       Impact factor: 5.554

3.  Is Body Mass Index the Best Adiposity Measure for Prostate Cancer Risk? Results From a Veterans Affairs Biopsy Cohort.

Authors:  Lourdes Guerrios-Rivera; Lauren Howard; Jennifer Frank; Amanda De Hoedt; Devon Beverly; Delores J Grant; Cathrine Hoyo; Stephen J Freedland
Journal:  Urology       Date:  2017-04-10       Impact factor: 2.649

4.  Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients.

Authors:  Jonas Busch; Mark L Gonzalgo; Natalia Leva; Michelle Ferrari; Hannes Cash; Carsten Kempkensteffen; Stefan Hinz; Kurt Miller; Ahmed Magheli
Journal:  World J Urol       Date:  2014-05-23       Impact factor: 4.226

Review 5.  Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors.

Authors:  Ernst Lengyel; Liza Makowski; John DiGiovanni; Mikhail G Kolonin
Journal:  Trends Cancer       Date:  2018-04-05

6.  Serum 17β-estradiol fails as a marker in identification of aggressive tumour disease in patients with localized prostate cancer.

Authors:  Thomas J Schnoeller; Julie Steinestel; Friedemann Zengerling; Andres J Schrader; Florian Jentzmik
Journal:  World J Urol       Date:  2015-04-24       Impact factor: 4.226

7.  Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Emma H Allott; Lauren E Howard; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2014-05-08       Impact factor: 5.588

8.  Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial.

Authors:  Scott P Kelly; Barry I Graubard; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook
Journal:  J Natl Cancer Inst       Date:  2016-10-20       Impact factor: 13.506

9.  First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

Authors:  Kagan Griffin; Ilona Csizmadi; Lauren E Howard; Gina-Maria Pomann; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Jennifer Beebe-Dimmer; Stephen J Freedland
Journal:  Cancer Causes Control       Date:  2019-01-30       Impact factor: 2.506

Review 10.  Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.

Authors:  Nikolaos Spyrou; Konstantinos I Avgerinos; Christos S Mantzoros; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.